The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RULE 2.10 UPDATE

4 Nov 2015 18:28

RNS Number : 6200E
Plethora Solutions Holdings PLC
04 November 2015
 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

4 November 2015

RULE 2.10 UPDATE

In accordance with 2.10 of the City Code on Takeovers and Mergers (the "Code), the Company confirms that as at the date of this announcement, it has 823,297,686 ordinary shares of £0.01 each in issue with ISIN GB00B06GL868. Plethora's ordinary shares are listed on the Alternative Investment Market of the London Stock Exchange ("AIM").

In addition, Plethora has a number of warrants, convertible loans and options/share awards outstanding (none of which have an associated ISIN number). Details of these securities are included below.

Mellon Bridge Loans: a convertible loan note due to be repaid on 31 March 2010. Upon redemption, the loan may be converted to 17,000,000 ordinary shares of 1p at an exercise price of 2p per share.

Galloway loan warrant instrument: a warrant granted to Galloway Limited to subscribe for ordinary shares of 1p representing up to 5% of the fully diluted ordinary share capital (post exercise) at a price of 1.25p per share. The warrant is due to expire on 31 March 2023 and can be exercised at any point up to this date at the discretion of Galloway. Based on the current fully diluted ordinary share capital, the warrant allows Galloway to subscribe for up to 54,118,431 shares.

CfE loan warrant instrument: a warrant granted to the Capital for Enterprise fund to subscribe for ordinary shares of 1p representing up to 3% of the fully diluted ordinary share capital (post exercise) at a price of 1p per share. The warrant is due to expire on 31 March 2023 and can be exercised at any point up to this date at the discretion of Capital for Enterprise. Based on the current fully diluted ordinary share capital, the warrant allows Capital for Enterprise to subscribe for up to 32,471,058 shares.

Fundraising Warrants: warrants attached to the capital fundraising undertaken in September 2014. Up to 101,148,981 ordinary shares of 1p may be subscribed at an exercise price of 15p.

LTIPs: share awards under the Company's Long Term Incentive Plan. A total of 54,200,000 ordinary shares of 1p each will be awarded at no subscription cost to employees based on various commercial milestones. Additionally the LTIPs will automatically vest on a change of control of Plethora.

Executive Share Option Scheme (ESOP): available to all employees and directors of the Company. A total of 132,460 ordinary shares of 1p each may be issued in relation to the scheme at a subscription price of 59p per share.

 

Romero Tayong

Company Secretary

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RTTLLFFTLRLSIIE
Date   Source Headline
26th Feb 20077:03 amRNSClinical Update - PSD510
22nd Feb 20077:02 amRNSClinical Update - PSD502
8th Feb 20077:01 amRNSClinical Update
21st Dec 20062:30 pmRNSTotal Voting Rights
5th Dec 20067:03 amRNSProduct Update - ErecAid
27th Nov 20067:01 amRNSProduct Update PSD401
9th Oct 20067:00 amRNSFDA grants label extension
4th Oct 200610:02 amRNSOptions Award
25th Sep 20067:04 amRNSFDA Approval
25th Sep 20067:03 amRNSInterim Results
13th Sep 200611:44 amRNSNotice of Results
22nd Aug 20067:01 amRNSSenior Management Appointment
22nd Aug 20067:01 amRNSClinical Update
10th Aug 20067:00 amRNSSenior Appointment
8th Aug 20067:01 amRNSClinical Update
22nd Jun 20067:02 amRNSIn-Licence and Placing
1st Jun 20067:01 amRNSRe Agreement
27th Apr 20064:11 pmRNSAnnual General Meeting
6th Apr 20064:47 pmRNSShare Options Award
4th Apr 20067:01 amRNSPrelim Results 31 Dec 05
16th Mar 20069:01 amRNSNotice of Results
2nd Mar 20067:00 amRNSFDA Accept Phase II ( PSD597)
21st Feb 20067:01 amRNSLicensing Agreement
13th Feb 20061:27 pmRNSHolding(s) in Company
10th Feb 200611:34 amRNSResult of EGM
6th Feb 200611:25 amRNSResult of EGM
3rd Feb 20065:30 pmRNSHolding(s) in Company
31st Jan 20065:02 pmRNSHolding(s) in Company
13th Jan 20067:30 amRNSProposed Acq and Placing
16th Dec 20057:00 amRNSPSD502 Final Clinical Data
7th Dec 200511:23 amRNSHolding(s) in Company
1st Dec 20057:00 amRNSPSD502 Clinical Trial Data
30th Nov 20052:22 pmRNSHolding(s) in Company
20th Oct 20057:00 amRNSPhase II Clinical Study
26th Sep 20057:03 amRNSInterim Results
26th Sep 20057:00 amRNSProduct Acquisition
12th Sep 20057:00 amRNSPhase II Clinical Trials
31st Aug 20059:38 amRNSNotice of Results
26th Jul 20057:00 amRNSClinical Update
13th Jul 20057:00 amRNSCollaborative Agreement
30th Jun 20058:30 amRNSShare Options Award
22nd Jun 20057:00 amRNSClinical Update
19th May 20057:00 amRNSDirector Dealings
28th Apr 20054:05 pmRNSHolding(s) in Company
18th Apr 20057:00 amRNSRoche Announcement
24th Mar 20058:00 amRNSFirst Day Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.